Summary : Spinal muscular atrophy is a common cause of disability in childhood and is characterized by weakness and wasting of voluntary muscle. It is frequently fatal. The gene for this disorder has been identiÐed as the SMN gene and is part of a highly complex duplicated region of chromosome 5 that is subject to a high rate of gene deletion and gene conversion. The severity of muscle weakness correlates with the amount of full-length SMN protein produced. Molecular genetic studies support a model in which patients are compound heterozygotes of deleted and converted alleles that predicts a progressively decreasing amount of protein product with severity of muscle weakness. The function of SMN is beginning to be understood and it appears to be involved in ribonucleoprotein biogenesis and thus indirectly in posttranscriptional processing of mRNA. There are theoretical grounds for motor neurons having a cell-speciÐc vulnerability to disturbances of mRNA processing and transport and these are brieÑy reviewed.
McKusickÏs database of genetic diseases, Mendelian Inheritance in Man (McKusick 1994) (http ://www.ncbi.nlm.nih.gov/omim/), lists over 30 genetic disorders involving motor neurons. While many of these are rare, taken together they impose a considerable burden of morbidity and mortality. Autosomal recessive proximal spinal muscular atrophy (SMA) is a particular form of inherited motor neuron disease that is common and has genetic and pathological features of unique interest. This review provides a background to understanding important recent developments in the molecular pathogenesis of this disease.
The central feature of the human motor system is the interaction between primary motor neurons in the motor cortex and secondary motor neurons in the interior horn of the segmental spinal cord. The cell bodies of secondary motor neurons lie within the central nervous system (CNS) but project their axons outside the CNS to form a Ðnal common pathway for the passage of nerve impulses to voluntary muscle. Most diseases of motor neurons either a †ect mixed upper and lower motor neuron cell populations or motor neurons as part of a generalized neurodegenerative process. SMA occupies a unique position among genetic disorders in a †ecting the lower motor neuron only.
Motor neurons arise from the neuroepithelium by a spatially and temporally regulated process controlled by a primary activating signal (the expression of the T albot signalling molecule Sonic hedgehog from the notocord) (Tanabe and Jessell 1996) . Development proceeds by the aggregation of specialized subtypes of motor neurons (under the regulation of speciÐc transcription factors) into groups according to their target muscle. Motor neurons become post-mitotic at a very early stage. The developing motor neuron cell bodies send out their axons towards the target muscle and between 40% and 80% of all motor neurons undergo programmed cell death in embryonic development (reviewed in Oppenheim 1991). The " selection Ï of motor neurons for survival is thought to be target dependent. In contrast to other forms of primarily degenerative motor neuron disease such as amyotrophic lateral sclerosis, SMA is probably best thought of as a failure of target-dependent motor neuron survival and as a developmental disorder due to an inherited deÐciency of motor neuron metabolism.
CLINICAL FEATURES
The term spinal muscular atrophy can literally be applied to any condition where the principal Ðnding is muscle weakness secondary to anterior horn cell degeneration. However, the term is usually restricted to a group of conditions that are genetically inherited and involve a pure lower motor neuron syndrome in which the pathological hallmark is isolated degeneration of the anterior horn cells. As described below, autosomal recessive SMA has core clinical features that make the distinction from other forms of SMA (e.g. distal, dominant) relatively easy.
SMA is a common disorder occuring in all racial groups in all areas of the world. It is estimated to be the second most frequent disease seen in paediatric neuromuscular clinics after Duchenne muscular dystrophy and the second commonest fatal autosomal recessive disease after cystic Ðbrosis. The combined incidence of the di †erent forms of SMA described below is approximately 1 in 6000È10 000 live births. The historical background of the emergence of SMA as a clinical syndrome has been reviewed by Dubowitz (1995) . What is now referred to as autosomal recessive proximal spinal muscular atrophy of childhood was Ðrst described by Werdnig in 1891 in two siblings with onset at around 10 months and death before the age of 6 years. Ho †mann described four families a †ected by a similar disease in 1894. In both WerdnigÏs and Ho †mannÏs cases, autopsy revealed degeneration of cells in the anterior horns with little or no evidence of involvement of other CNS regions.
Type I SMA in the currently used classiÐcation (the eponymous title WerdnigÈ Ho †mann disease has historically been applied to the neonatal form of SMA) presents with weakness before the age of 6 months. In a signiÐcant proportion of cases there is onset in utero and mothers describe a reduction or abolition of fetal movements in the third trimester. A †ected children are hypotonic and are never able to sit unaided. Proximal muscles are a †ected more than distal muscles and the lower limb more than the upper limb. There is usually evidence of bulbar involvement and this may lead to early feeding difficulties. Prominent weakness of the respiratory muscles, with a striking absence of diaphragmatic involvement, inevitably leads to death through respiratory infection before the age of 2 years.
